IV Ketamine Infusions for the Treatment of Depression: An Evidence Based Practice Analysis
Sergio A. Quinones, DNAP, CRNA
- Sigma Affiliation
Visits vs Downloads
Visitors - World Map
Top Visiting Countries
Top Visiting Cities
Visits (last 6 months)
Downloads (last 6 months)
Popular Works for Quinones, Sergio A. by View
Popular Works for Quinones, Sergio A. by Download
According to the World Health Organization, major depressive disorder (MDD) is a mental health condition which affects a significant portion of the worldwide population and is projected to become the leading cause of disability by 2020. There are several treatment options for the diagnosis of depression, with the most popular being antidepressant drugs such as the selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs); and electroconvulsive therapy (ECT). The significant drawbacks to the current treatments are the extended timeframe required for drugs to reach therapeutic efficacy and resistance to ECT over time. These disadvantages can lead to increased risk of self-harm and suicidal tendencies. A drug with fast onset and efficacy in treating depression can improve patient’s quality of life.
|Type||Other Graduate Paper|
|Review Type||Faculty Approved: Degree-based Submission|
|Research Approach||Pilot/Exploratory Study|
|CINAHL Subject(s)||Antidepressive Agents--Administration and Dosage;
Ketamine--Administration and Dosage;
Depression--Prevention and Control;
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.